Comparative oncology is experiencing a growth surge fueled primarily by increased federal funding and better tools to study spontaneous canine cancers. Dogs can serve as a translational, immunocompetent model that bridges the gap between preclinical findings in mice and successfully advancing therapies into humans.

You do not currently have access to this content.